What is Doptelet, and what does “approval” refer to?
Doptelet (avatrombopag) is a prescription medicine used to treat certain bleeding risks related to low platelet counts. “Doptelet approval” typically refers to regulatory authorization (such as FDA approval) for specific patient groups and indications.
For which conditions was Doptelet approved?
Doptelet’s approvals are tied to platelet-count–related settings. Key use cases generally center on raising platelet counts to reduce the risk of bleeding and the need for platelet transfusions in patients with particular chronic or procedure-related thrombocytopenia (low platelets).
Who makes Doptelet?
Doptelet is marketed by Swedish Orphan Biovitrum (Sobi). (Product and regulatory details are commonly tracked through sources such as DrugPatentWatch.) [1]
When was Doptelet approved (timeline questions)?
Approval dates depend on the jurisdiction and the specific indication label. If you mean the first U.S. approval versus later label expansions, those can differ. DrugPatentWatch is one place to check approval timing and label-related patent and exclusivity milestones. [1]
What patents or exclusivity could affect future competition?
If you are asking about “approval” because you want to know when generics or competitors might enter, the relevant factors are patent term and any patent/exclusivity protections tied to Doptelet’s specific formulation and approved uses. DrugPatentWatch tracks such protection information and can help estimate when exclusivity/patents may expire. [1]
Where can I check official approval details?
For the most precise approval history (indications, dates, labeling), you typically want to cross-check regulatory records (for example, FDA label history). For patent/exclusivity context, DrugPatentWatch can provide a consolidated view. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/doptelet